Kornimate/medical-research-clean huggingface dataset:
validation of hepafat-scan for noninvasive measurement of steatosis in youth

Conditions: Non-alcoholic Fatty Liver Disease

Summary: the purpose of this study is to see if the hepafat-scan (a special sequence of images done in a mri) can accurately detect the amount of fat in the liver.

the leading cause of liver disease for both adults and children in the us is nonalcoholic fatty liver disease (nafld), an obesity-related liver disease closely associated with the metabolic syndrome. nafld increases the risk of liver disease but also increases risk of type ii diabetes, cardiovascular disease (cvd) and the metabolic syndrome. invasive liver biopsy has been considered the best diagnostic tool for confirming nafld. this study will establish magnetic resonance imaging (mri) / magnetic resonance spectroscopy (mrs) as a quantitative noninvasive "virtual biopsy" and benefit the health of children with liver diseases by decreasing risk and improving diagnosis. specifically, in nafld, this fat quantification protocol will be broadly useful in future research studies, including therapies for nafld as well as for patient diagnosis and follow-up.

Eligibility criteria:
inclusion criteria: * boys and girls age 7-18 years * scheduled for a clinically indicated liver biopsy * able to undergo mri without sedation * written informed consent from parent or legal guardian * written informed assent from the child when indicated by age exclusion criteria: * renal disease with a creatinine \> 2 or requiring dialysis * metal, braces or other implanted devices not compatible with mri * not willing to try to hold still for an un-sedated mri * pregnancy * failure to give consent or assent

Keywords: hepafat-scan liver disease pediatrics
continuous glucose monitoring in diabetes and prediabetes

Conditions: Diabetes Mellitus, Type 2; PreDiabetes; Obesity

Summary: evaluate the use of brief serial real time continuous monitoring (rt-cgm) as a behavior modification tool in obese patients with prediabetes and diabetes. after receiving rt-cgm, nutrition and exercise education, participants will be able to monitor their blood sugar in real time for 2 sessions . education on how to interpret cgm in the setting of food choices and exercise coupled with nutrition and exercise information should lead to improved weight and other nutritional and exercise changes.


Eligibility criteria:
inclusion criteria: 1. age 18-55 2. prediabetes (a1c 6.0-6.4) or diabetes (a1c 7.0-10) 3. bmi ≥ 30 kg/m2 4. willing to wear pedometer during study period 5. able to walk 2 city blocks at baseline without assistance (self-reported) 6. reading level at least 6th grade in english 7. expected to remain in local community for at least 4 months 8. either is not treated with or has been on a stable treatment regimen of any of the following medications for a minimum of 3 months prior to visit 1 (screening/enrollment): 1. sulfonylureas 2. biguanidine 3. thyroid replacement therapy 4. glp-1 agonists 5. sodium-glucose co-transporters 6. basal insulin 7. thiazolidinediones 8. hormone replacement therapy (female subjects) estrogen/progesterone products 9. oral contraceptives/birth control (female subjects) 10. antidepressant agents (ssris, paxil, prozac, celexa, zoloft, etc.) 9. is able to read, understand, and sign the informed consent form (icf) and if applicable, an authorization to use and disclose protected health information form (consistent with health insurance portability and accountability act of 1996 \[hipaa\] legislation), communicate with the investigator, and understand and comply with protocol requirements. exclusion criteria: 1. women who are pregnant, lactating, planning to become pregnant 2. subjects who are taking amphetamines, anabolic, or weight-reducing agents 3. contraindications to moderate exercise 4. pre-prandial insulin 5. on any antipsychotic medication or history of schizophrenia or bipolar disorder 6. daily use of any form of steroid medication (oral, inhaled, injected) within the last 3 months 7. active wounds or recent surgery within 3 months 8. inflammatory disease, or chronic and current use of anti-inflammatory drugs or narcotics 9. active cardiovascular diseases within 12 months of visit 1, such as myocardial infarction, clinically significant arrhythmia, unstable angina, coronary artery bypass surgery, or angioplasty; or are expected to require coronary artery bypass surgery or angioplasty during the course of the study 10. presence or history of severe congestive heart failure (new york heart association class iv \[ccnyha 1994\]) 11. has evidence of current abuse of drugs or alcohol or a history of abuse that, in the investigator's opinion, would cause the individual to be noncompliant 12. enrolled in another weight loss program 13. already receiving continuous glucose monitoring (cgm)
18f labeled fap targeted molecular probe in early tumor diagnosis

Conditions: Lung Cancers; Pancreatic Cancer; Neuroendocrine Tumors; Thyroid Cancer

Summary: evaluate the safety of the novel fap targeted molecular probe 18f-fapi-yq104 labeled with radioactive isotopes in clinical applications and verify its effectiveness in tumor diagnosis.


Eligibility criteria:
inclusion criteria: - 1. volunteer for the trial, with the patient or their legal guardian signing the informed consent form; 2. volunteers are not limited by gender, and the age range is from 18 to 75 years old, including both ends; 3. other imaging examination methods (ct, mri, etc.) revealed tumor occupying lesions; 4. patients with lung cancer, thyroid cancer, pancreatic cancer, melanoma, and neuroendocrine tumors who can obtain the final pathological results. 5. kidney: gfr \> 50 ml/min, erpf \> 280 ml/min, platelet count (plt) \> 75,000/μl, white blood cell (wbc) \> 3,000/μl, alanine aminotransferase (alt) and aspartate aminotransferase (ast) levels less than 3 times the normal value. exclusion criteria: * 1. individuals with a history of allergies to similar drugs (drugs with similar chemical or biological components to fapi), allergic constitution, or current allergic diseases; 2. those who are currently conducting clinical research on other drugs or have participated in any clinical research on drugs (excluding vitamins and minerals); 3. there are other clinical problems that are difficult to control (such as hiv, hepatitis c virus infection or active hepatitis b, or other serious chronic infections and serious mental, neurological, cardiovascular, respiratory and other system diseases); 4. red blood cell rbc\<4 × 1012, white blood cell wbc\<3 × 109, hemoglobin\<110g/l, plt\<75000×109； 5. significant abnormalities in liver and kidney function, with gfr less than 50 ml/min; 6. tumor burden greater than 50%, or significant spinal cord compression; 7. expected survival period is less than six months; chemotherapy within june; 8. having severe acute comorbidities or severe refractory mental disorders; 9. pregnant and lactating women (where pregnancy is defined as a positive urine pregnancy study); 10. patients whose physical condition is not suitable for radiation examination; 11. other situations that researchers consider unsuitable for participating in the experiment.
multicenter phase i study of hrs-6208 in patients with solid tumors

Conditions: Solid Tumors

Summary: this is an open, multicenter phase i study to evaluate the safety and tolerability of hrs-6208 in patients with advanced solid tumors.


Eligibility criteria:
inclusion criteria: 1. patients with unresectable locally advanced or metastatic solid tumors confirmed by histology or cytology who have relapsed or progressed after standard treatment, or have no standard treatment options, or do not apply standard treatment at this stage; 2. age 18\~75 years old; 3. at least one measurable lesion per recist v1.1 criteria; 4. ecog ps score: 0-1. exclusion criteria: 1. history of other malignancies within the past 5 years, excluding cured basal cell carcinoma of the skin and carcinoma in situ of the cervix; 2. the adverse reactions of previous anti-tumor therapy have not recovered to nci-ctcae v5.0 grade evaluation ≤ 1; 3. he has severe cardiovascular and cerebrovascular diseases; 4. severe infection within 4 weeks prior to the first dose.
bihemispheric modulation of the motor cortex by transcranial direct current stimulation in subacute stroke patients

Conditions: Stroke

Summary: post-stroke sensorimotor recovery largely depends on ipsilesional and interhemispheric motor circuit reorganization. transcranial direct current stimulation (tdcs) may be used to enhance after-effects of rehabilitation through membrane polarization modulation. in this double-blind, crossover randomized controlled trial, we aim to investigate whether single-session, bihemispheric tdcs to the primary motor cortex (m1) in combination with upper extremity rehabilitation therapy modulates ipsilesional motor circuit excitability using transcranial magnetic stimulation (tms) and magnetoencephalography (meg) measures.

we will consecutively enroll subacute (2-4 weeks after stroke onset) patients with first-time, unilateral, ischemic subcortical stroke in the middle cerebral artery territory with mild to moderate hand weakness. all subjects will be assessed for baseline upper extremity motor function (fugl-meyer test and action research arm test), structural and functional magnetic resonance imaging (fmri). a single session of bihemispheric tdcs (anodal tdcs to ipsilesional m1 and cathodal tdcs to contralesional m1 with 2 ma stimulation for 20 min) or sham tdcs (same but stimulation for only 2 min) with simultaneous physical/occupational therapy will be tested in each subject with a randomized sequence on different days (at least two days apart from each other). all stroke patients will receive standard medical and rehabilitation treatments during the study period. changes in corticospinal excitability and transcallosal inhibition from the tms study, as well as sensorimotor oscillations, meg source projection, and functional connectivity from the task-related meg will be assessed immediately before and after intervention.

Eligibility criteria:
inclusion criteria: * subacute (2-4 weeks after stroke onset) patients * first-time, unilateral, ischemic subcortical stroke in the middle cerebral artery territory * mild to moderate hand weakness (mrc 2-4/5) exclusion criteria: * cerebral cortex lesions * containing metal implants (such as implanted electrodes, pacemakers) * sensitive or fear of electromagnetic waves * pregnant women * history of alcohol or drug abuse * history of seizures or epilepsy eeg recording * other significant disease or neuropsychiatric disorders * claustrophobia * fixed dentures over two or more (enough to interfere with meg signals)

Keywords: neuroplasticity
binocular vision alternations and fmri activation after icl implantation for high myopia

Conditions: Binocular Vision Disorder

Summary: implantable collamer lens (icl) is one of the most effective operation for high myopia. due to refractive correction changed, and prism effect of the spectacle removed, in the early stage after icl implantation, binocular function might be dysfunction, leading to asthenopia, blurred vision, double vision and so on. this study will recruit the high myopia subjects that scheduled for icl implantation, purpose to investigate the binocular vision alternations and brain activation that impacted by icl implantation.


Eligibility criteria:
inclusion criteria: * age 18-35 * spherical equivalent over -6.00ds, astigmatism within -2.00dc, anisometropia within -2.00ds * bcva ≥ 0.8 * plan to accept implantable collamer lens surgery * near point of convergence within 10cm * positive fusion vergence over 20pd exclusion criteria: * stabismus * previous ocular surgery or trauma * history of vision therapy * monovision and nystagmus * mental disease or craniocerebral trauma

Keywords: binocular vision, accommodation, vergence, fmri
bag mode breathid hp validation versus endoscopy in detection of helicobacter pylori

Conditions: Helicobacter Pylori Infection

Summary: a new method of breath collection for testing for helicobacter pylori infection has been developed by exalenz. in this study, it will be compared to the gold standard- endoscopy results to prove its accuracy.

this study will validate a breath collection method by comparing a newly developed breath test kit, idkit:hp™ two using breath collection bags, to congruent biopsy results (a composite reference standard by analyzing specimens with microbial culture, histological examination and rapid urease test- rut) in detecting h.pylori

Eligibility criteria:
inclusion criteria: * present with clinical indication of h. pylori and candidate for upper endoscopy * have the ability and willingness to sign the informed consent form for initial diagnosis cohort * naive to treatment in the past 18 months * no known h.pylori status (no conclusive test results within last 6 months) exclusion criteria: * participation in other interventional trials * antibiotics and/or bismuth preparations within four (4) weeks prior to breath test * ppi (proton pump inhibitors) or h2 blockers within two (2) weeks prior to breath test * pregnant or breastfeeding women * allergy to test substrates

Keywords: h.pylori
caffeine for apnea of prematurity (cap)

Conditions: Apnea of Prematurity

Summary: at least 5 of every 1000 live-born babies are very premature and weigh only 500 to 1250 grams at birth. approximately 30-40% of these high-risk infants either die or survive with lasting disabilities. the aim of this research is to reduce this heavy burden of illness. a multi-center randomized controlled trial has been designed in which 2000 very low birth weight infants will be enrolled. our goal is to determine whether the avoidance of methylxanthine drugs will improve survival without disability to 18 months, corrected for prematurity. methylxanthine drugs such as caffeine are used to prevent or treat periodic breathing and breath-holding spells in premature infants. however, there is a striking lack of evidence for the long-term efficacy and safety of this therapy. methylxanthines block a naturally occurring substance, called adenosine, which protects the brain during episodes of oxygen deficiency. such episodes are common in infants who are treated with methylxanthines. it is possible that methylxanthines may worsen the damage caused by lack of oxygen. therefore, this trial will clarify whether methylxanthines cause more good than harm in very low birth weight infants.


Eligibility criteria:
inclusion criteria: * birthweight 500 to 1250 grams * postnatal age day 1 to day 10 * infant considered a candidate for methylxanthine therapy by clinical staff exclusion criteria: * dysmorphic features or congenital malformations that adversely affect life expectancy or neurodevelopment * unlikely to comply with long-term follow-up * prior treatment with a methylxanthine

Keywords: preterm infants very low birthweight apnea of prematurity methylxanthines developmental disabilities
standard follow-up program neuro-oncology patients (sfp neuro-oncology)

Conditions: Neurological Cancer

Summary: standardised evaluation of baseline data regarding tumor-, patient- and treatment-characteristics as well as follow-up data regarding tumor- and clinical-outcome of neuro-oncology patients treated with radical/curative radiotherapy. motive: currently there is limited data on dose-effect relationships of tissues and structures in and around the brain. this lack of knowledge hampers patient selection for proton therapy, technique innovations, and accurate prediction of treatment outcome. goal: to evaluate the selection for radiation treatment, obtain more knowledge on dose-effect relationships and enable insight in necessary treatment technique innovations that would improve treatment outcome.


Eligibility criteria:
inclusion criteria: * patient with neuro-oncological cancer * patient receiving a radiotherapy dose xxx gy exclusion criteria: * failure to comply with any of the inclusion criteria

Keywords: acute toxicity late toxicity prediction models
probiotics in iga nephropathy

Conditions: IgA Nephropathy

Summary: recent studies have shown an increased gastrointestinal reactivity and increased intestinal permeability in iga nephropathy (igan). probiotic supplementation is known to impact the gastrointestinal immune system possibly by improvement of both the immunologic and the non-immunologic intestinal barrier. probiotic supplementation should thus theoretically have an effect on igan. in this study the investigators will study the efficacy and safety of lactobacillus reuteri.


Eligibility criteria:
inclusion criteria: * above 18 years * primary igan, verified by biopsy * albuminuria \> 0.75 g/24 h (verified by at least four sample results within a two years period prior to inclusion) * serum creatinine less than 200 umol/l (verified by at least four sample results within a two years period prior to inclusion) * having signed informed consent form exclusion criteria: * participation in another clinical intervention trial * patients with celiac disease * patients with secondary igan * creatinine clearance below 30 ml/min (mean of 3 measurements) * introduction of an ace inhibitor or angiotensin ii receptor blocker during the last three months prior to inclusion * patients treated with immunosuppressive or systemic corticosteroid drugs within the last twelve months * patients using probiotic products within the last three months (includes probiotic milk products) * known allergy or intolerance to any of the ingredients in the probiotic product
primary care based depression prevention for adolescents/young adults/young adults and young adults

Conditions: Depression

Summary: the purpose of this research is to evaluate the feasibility of an interview between an adolescent / young adult and a pcp (primary care physician).

a web-based depression prevention program will evaluate the interview. depression is a condition where people feel sad, tired, have changes in sleep, and lose interest in fun things for more than two weeks. this program teaches adolescents/young adults new skills. they learn new skills by talking with their doctor and doing a workbook at an internet site. counselors have used some of these lessons to successfully treat, and in some cases, prevent depression. we do not know if these lessons given in a primary care doctor's office or over the internet will prevent depression. we will have to do further studies to determine this. if subjects are clinically depressed right now, they cannot be a part of this study.

Eligibility criteria:
inclusion criteria: * age 15-21 years and * two risk factors for developing depression in the next two years: * center for epidemiologic studies-depression (ces-d) score \> 12 and either a family history or past personal history of depression. * exclusion criteria include meeting criteria or undergoing active treatment for m. depression, or having suicidal ideation exclusion criteria: * undergoing active treatment for m. depression, or having suicidal ideation

Keywords: depression in adolescents and young adults, depression web-base activity
strength at home: veterans' program (ptsd-focused therapy for anger and relationship conflict among oef/oif veterans)

Conditions: Domestic Violence

Summary: this is a research study funded by the department of defense to test a therapeutic intervention for male combat veterans who engage in intimate partner violence (ipv). the investigators hope to decrease the recurrence of relationship aggression and help veterans manage anger. the primary aim of the study is to test the intervention.

the purpose of this project is to develop, standardize, and test an intervention for combat veterans exposed to trauma who engage in intimate partner aggression (ipa). this intervention, formerly labeled ptsd-focused cognitive behavior therapy for partner violence (pfcbt), and currently called the strength at home, veteran's program, incorporates components of interventions for ipa and trauma and will target mechanisms implicated in the relationship between trauma and ipa. this project addresses a number of the research gaps in this area of research including: (a) the development of a novel treatment approach to improve functioning and well-being of affected individuals; (b) tertiary prevention (of repeated ipa) during re-integration; and (c) examination of the efficacy of a program providing support for the families and caregivers of veterans with combat history.

Eligibility criteria:
inclusion criteria: * any era veteran * over the age of 18 * in a relationship within a female partner within the last 6 months * at least one act of male-to-female physical aggression over the previous 6 months or at least one act of male-to-female severe violence in the past 12 months * male participant must consent for partner contact exclusion criteria: * participant evidences severe organicity or active psychosis * reading difficulties prevent valid completion of the assessment instruments * participant expresses prominent suicidal or homicidal ideation * participant meets diagnostic criteria for alcohol and/or drug dependence, if not in early full remission or sustained partial remission

Keywords: ptsd cbt intimate partner violence treatment
cardiac surgery and postoperative organ dysfunction

Conditions: Postoperative Complications

Summary: the aim of the study is to identify the correlation between ischaemia reperfusion injury and postoperative multiorgan damage during cardiopulmonary cardiac surgery; and to investigate biomarkers that can predict postoperative organ damage in cardiac surgery.

this study proposes to observe multi-organ functional impairment of the heart, kidney and brain after extracorporeal circulation in a prospective study of clinical patients; to obtain markers with diagnostic and predictive efficacy by collecting pre and postoperative serum and heart and ear tissue samples from patients with postoperative organ functional impairment, performing combined proteomic and metabolomic analyses, and by analysing them with detailed postoperative clinical prognostic data using machine learning algorithms.

Eligibility criteria:
inclusion criteria: 1. age ≥50 years; patients requiring mitral valve replacement surgery or mitral valve plus aortic valve replacement under cardiopulmonary bypass 2. agreed to participate in this study, and signed the informed consent form. exclusion criteria: 1. history of neurological disease (stroke, reversible ischemic hypoxia, transient ischemic attack, or neurodegeneration) ; 2. patients with severe preoperative renal insufficiency (serum creatinine \> 442 μmol/l or need renal replacement therapy) , 3. liver dysfunction (child-pugh grade c) 4. myocardial infarction within 4 weeks 5. asa grade ≥ v